Due to concerns around sex-dependent outcomes in diabetes, we sought to evaluate whether the inhibition of myostatin in combination with insulin therapy would result in similar effects on the skeletal muscle and bone phenotype of female, insulin-deficient diabetic mice, compared to what we have previously shown in male mice. Here, MSTN is linked to diabetes mellitus.